This version is not peer-reviewed
Remdesivir: A Review of Its Discovery and Development Leading to Human Clinical Trials for Treatment of COVID-19
: Received: 16 April 2020 / Approved: 17 April 2020 / Online: 17 April 2020 (13:02:03 CEST)
A peer-reviewed article of this Preprint also exists.
Journal reference: ACS Central Science 2020
The global pandemic of SARS-CoV-2, the causative viral pathogen of COVID-19, has driven the biomedical community to action – to uncover and develop anti-viral interventions. One potential therapeutic approach currently being evaluated in numerous clinical trials is the agent remdesivir, which has endured a long and winding developmental path. Remdesivir is a nucleotide analog prodrug that perturbs viral replication, originally evaluated in clinical trials to thwart the Ebola outbreak in 2014. Subsequent evaluation by numerous virology laboratories demonstrated the ability of remdesivir to inhibit coronavirus replication, including SARS-CoV-2. Here, we provide an overview of its mechanism of action, discovery, and the current studies exploring its clinical effectiveness.
SARS-CoV-2; COVID-19; coronavirus; remdesivir
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.